Cancer remains one of the most formidable health challenges worldwide, affecting millions every year.
According to a study by Cancer Research UK, it’s estimated that there were 18.1 million new cancer diagnoses globally in 2020. This alarming figure underscores the rising trend in cancer diagnoses, the study states, “Worldwide there will be 28 million new cases of cancer each year by 2040.”
It’s not just about the overwhelming statistics but its profound impact on patients and their families. The treatment landscape, although progressing, still yearns for innovative breakthroughs.
NANOBIOTIX and NBTXR3
NANOBIOTIX, a biotechnology firm aiming to provide new treatment solutions for cancer patients, has recently welcomed Dr. Louis Kayitalire as their chief medical officer. Dr. Kayitalire boasts a prolific background in the biopharmaceutical sector, primarily focusing on oncology. He has been an integral part of the development and commercialization of various oncology therapeutics.
Laurent Levy, co-founder and chairman of NANOBIOTIX, praised Dr. Kayitalire’s innovative clinical acumen, asserting that his experience would be paramount in forwarding the company’s ventures, especially regarding NBTXR3.
Dr. Kayitalire previously held significant roles at major companies like F-star Biotechnology, Bristol-Myers Squibb, Celgene, and Eli Lilly. He expressed his excitement about the potential of NBTXR3 in changing the landscape of cancer treatment.
NBTXR3 Overview
NBTXR3, a unique oncology product, comprises hafnium oxide nanoparticles. Administered via a single intratumoral injection, it is then activated using radiotherapy. The primary goal is to cause significant tumor cell death in the injected area upon activation, which should then stimulate an adaptive immune response against the cancer.
NANOBIOTIX believes that due to its mode of action, NBTXR3 could be adapted for any solid tumor treatable with radiotherapy and combined with any therapeutic combination, especially immune checkpoint inhibitors.
Current evaluations for NBTXR3 involve its application in various solid tumors either as a standalone or in combination with anti-PD-1 immune checkpoint inhibitors.
Furthermore, NANOBIOTIX has embarked on collaborations to simultaneously develop the product while focusing on its primary developmental pathways. Partnerships include those with The University of Texas MD Anderson Cancer Center, LianBio, and recently with Janssen Pharmaceutica NV.
About NANOBIOTIX
Founded in 2003 and based in Paris, France, NANOBIOTIX is an advanced clinical biotechnology company. They are determined to redefine treatment outcomes for numerous patients by introducing groundbreaking physics-based therapeutic strategies.
The company holds over 20 umbrella patents linked to three distinct nanotechnology platforms. These platforms cater to oncology, bioavailability and biodistribution, and central nervous system disorders. Their principal focus is the development of NBTXR3, which has already received a CE marking in Europe for soft tissue sarcoma treatment under the brand name Hensify®.
While NANOBIOTIX remains a pivotal player in the field, other startups also contribute significantly to advancements in cancer treatment.
Among the many startups in this domain, Nanogenics stands out. They are a leading therapeutic provider that harnesses nanoscale technology and utilises siRNA to treat cancer and fibrotic diseases.
By leveraging their proprietary gene delivery technology, LipTide, they are adept at precisely delivering therapeutic siRNAs. Their premier drug, ECP-102, enhances the efficacy of chemotherapy by increasing the vulnerability of cancer cells to cell death.
Conclusion
The evolving landscape of cancer treatment is witnessing groundbreaking advancements spearheaded by entities like NANOBIOTIX. With the introduction of pioneering therapies, the future holds promise for more effective and diverse solutions in battling this global health crisis. Similarly, the contributions of startups such as Nanogenics emphasise a collective drive in the biotech community to push boundaries, offering hope and a brighter prognosis for patients worldwide.
News
Scientists Just Discovered a Cellular Survival System That Was Never Supposed To Exist
A surprising backup pathway allows cells to make a crucial amino acid when their primary machinery fails. For decades, biologists believed cells had only one way to access a molecule they cannot live without. New [...]
Artificial cells gain porous membranes, enabling lab reactions and drug release
Artificial cells created in the laboratory offer a wide range of potential applications. Until now, however, their membranes—unlike those of real cells—have been virtually impermeable. Researchers at the Max Planck Institute for Polymer Research, [...]
Popular Weight-Loss Drugs Like Ozempic Linked to Lower Breast Cancer Risk
Ozempic and similar weight-loss drugs were linked to a striking 30% reduction in breast cancer risk in a study of more than 110,000 women. Popular weight-loss and diabetes medications such as Ozempic, Wegovy, Mounjaro, [...]
Stanford Scientists Discover Explosive New Type of Immune Cell
Scientists studying the remarkable regenerative abilities of planarian flatworms have uncovered a previously unknown type of immune cell with an unusually destructive defense strategy. What if an immune cell could wipe out nearby threats [...]
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery
Bay Area biotech SonoThera is bubbling to a clinical boil after raising a $125 million series B with the backing of some of the biggest names in pharma. Vida Ventures led the raise, with the venture [...]
Joint initiative of 5 EU countries calls for ‘unified approach’ to pharma framework amid US drug pricing pressure
With drug pricing pressure building from the U.S., a healthcare-focused consortium of five European countries is calling for a “unified approach” to strengthen Europe’s pharmaceutical framework and access to innovative medicines. Belgium, the Netherlands, [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
NanoMedical Brain/Cloud Interface – Explorations and Implications. A new book from Frank Boehm
New book from Frank Boehm, NanoappsMedical Inc Founder: This book explores the future hypothetical possibility that the cerebral cortex of the human brain might be seamlessly, safely, and securely connected with the Cloud via [...]
New book from Nanoappsmedical Inc. – Global Health Care Equivalency
A new book by Frank Boehm, NanoappsMedical Inc. Founder. This groundbreaking volume explores the vision of a Global Health Care Equivalency (GHCE) system powered by artificial intelligence and quantum computing technologies, operating on secure [...]
UCLA Scientists Uncover a “Hidden Weakness” in Some of the World’s Deadliest Cancers
A new study has uncovered an unexpected vulnerability in some of the deadliest cancers. Researchers at UCLA have identified a previously hidden weakness in some of the most aggressive cancers, pointing to a possible new way [...]
AI-designed universal coronavirus vaccine clears first human trial
Key Takeaways Super-Antigen Technology: Uses AI and machine learning to analyze viral genomes, creating a single vaccine that targets essential features across entire virus families, including coronaviruses and Ebola. Human Trials & Safety: Phase [...]
Researchers Discover a Hidden Vitamin D Problem That Persists Year-Round
A new study suggests that some groups may not experience the expected seasonal boost in vitamin D levels, even during the sunniest months of the year. Many people assume that spending more time outdoors [...]
Researchers Solve the Mystery Behind a Billion-Dollar Dental Implant Disease
Researchers have uncovered why a common and costly dental implant infection often resists antibiotics. Dental implants have helped tens of millions of people regain a full set of stable, functional teeth, something traditional dentures [...]
Nanoparticles inspired by lung fluid improve therapies targeting respiratory system
The CIC biomaGUNE Center for Cooperative Research in Biomaterials has developed pulmonary surfactant nanoparticles (the blend of lipids and proteins that line the alveoli and enables breathing), which are encapsulated [...]
Scientists Finally Uncover How a “Forever Chemical” Causes Birth Defects
PFDA, a PFAS “forever chemical,” can cause craniofacial birth defects by disrupting retinoic acid regulation during fetal development, revealing the first clear molecular mechanism behind the link. Researchers have long linked perfluoroalkyl and polyfluoroalkyl substances (PFAS), [...]
